WALL STREET TRADER
Corp Update – Time To Buy !
Pressure BioSciences Inc
The company intends to hold a special shareholders meeting on Dec 30, 2021 at 4 PM EDT at the corporate headquarters. An up to date screen shot of PBIO’s present condition can be found In the Proxy BELOW
These shares have consolidated recently due to holiday market conditions and slowing stock market activities. This may be the right time to take advantage of the slow trading in the shares of PBIO. We continue to anticipate a BREAKOUT above the $4.50 level.
Much is happening and many traders are not taking advantage of bargain price levels due to tax selling and holiday malaise
A quick bounce back to normal levels is predicted after Dec 22, 2021
Watch this compelling video explaining in detail the products and medical devices that Pressure Bio Sciences offers the medical and scientific community Must See Corp Video .
Investor Contact – Gary Zwetchkenbaum- Plum Tree Consulting LLC –Cell : 516 – 455-7662 – EMAIL – firstname.lastname@example.org
Operational and Technical Achievements Set Stage for Expected Major Growth and Profitability in 2022
Investor Call Scheduled for Wednesday, November 17, 2021 at 4:30 p.m. ET
SOUTH EASTON, MA / ACCESSWIRE / November 17, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agriculture, and food & beverage industries, today reported financial results for the third quarter ended September 30, 2021, provided a business update, and offered guidance for an expected strong 2022.
Financial Highlights: Q3 2021 vs. Q3 2020 (rounded to nearest hundred except EPS)
- Total revenue for Q3 2021 was $518,000 compared to $534,000 for the Q3 2020, a decrease of 3%.
- Instrument sales for Q3 2021 were $274,200 compared to $312,700 for Q3 2020, a decrease of 12%.
- Consumable sales for Q3 2021 were $46,000 compared to $49,000 for Q3 2020, a decrease of 7%.
- BaroFold/UST services in Q3 2021 were $99,700 compared to $84,200 for Q3 2020, an increase of 18%.
- New PBI Agrochem subsidiary had initial sales in Q3 2021 of $17,210 (no sales in Q3 2020).
- Operating loss for Q3 2021 was $1,243,000 compared to $819,000 for Q3 2020, an increase of 51%.
- Basic and diluted net loss per share was $(0.82) for Q3 2021 improved from $(1.02) for Q3 2020.
Financial Results: September 2021 YTD vs. September 2020 YTD (rounded to nearest hundred except EPS)
- Total revenue for Sept 2021 YTD was $1,687,000 compared to $1,056,000 for Sept 2020 YTD, a 60% increase.
- Instrument sales for Sept 2021 YTD were $989,500 compared to $568,500 for Sept 2020 YTD, a 74% increase.
- Consumable sales for Sept 2021 YTD were $191,400 compared to $156,200 for Sept 2020 YTD, a 23% increase.
- BaroFold/UST services for Sept 2021 YTD were $241,800 vs. $128,100 for Sept 2020 YTD, an 89% increase.
- Operating loss for Sept 2021 YTD was $(2,964,000) vs. $(3,544,000) for Sept 2020 YTD, a 37% improvement.
- Basic and diluted net loss per share was $(3.02) for Sept 2021 YTD improved from $(4.22) for Sept 2020 YTD.
Mr. John B. Hollister, Director of Sales and Marketing for PBI, commented: “Despite supply chain issues adversely affecting operations, our Q3 2021 financial results were effectively on par with the strong results of Q3 2020. Importantly, our 2021 YTD financial results – including total revenue, instrument & consumable sales, and BaroFold/UST services – maintained our strong improvement trend compared to the same 9-month period in 2020. Significantly, anticipation for our eco-friendly agrochemical product sales in Q4 2021, followed by the release of our much-anticipated UST platform for leasing and licensing in the early part of 2022 continues to build. We are receiving numerous unsolicited calls every week from a variety of markets regarding our product introduction timetable to help deliver better nanoemulsified products via the UST process. We are very excited about the expected impact we believe our UST platform release will have in 2022.”
Q3 2021 Operational and Technical Highlights
- Set up a U.S. warehousing, processing, and product packaging facility for our new PBI Agrochem subsidiary.
- Reported the successful UST nanoemulsification processing of Astaxanthin and Neem Oil.
- UST processed nanoemulsions of CBD oil in water soared past our one-year stability goal – now at 18 months.
- Enacted strategic expansion of BaroFold refolding program with successful debut of instrument sale/lease program.
- Announced plans to set-up Toll Manufacturing partnerships on the east and west U.S. coasts.
- Unveiled aggressive goals for Q4 2021 & FY 2022, including NASDAQ/NYSE Uplist, Agrochem Acquisition, and Profitability.
Mr. Richard T. Schumacher, President and CEO of PBI, commented: “The many successes of the 2021 third quarter have set the stage for continued foundation building in Q4, in preparation for anticipated major growth in 2022. We believe our achievements in Q4 2021 and FY 2022 will be many, and will include: (i) significant increases in agrochem revenue; (ii) shipment of the industrial-scale UST system to our partner The Ohio State University (“OSU”); (iii) announcement of progress made by the OSU/PBIO Consortium leveraging UST for improved food quality, safety and stability; (iv) commercial release of the UST platform; (v) executed fee-for-service contracts for UST toll processing; (vi) up-listing of PBIO to a national stock exchange; and (vii) profitability by or before the end of 2022. Our team and our partners are highly motivated by PBI’s recent successes and strengthening, but we believe the best is yet to come.”
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
Pressure BioSciences Awarded Second U.S. Patent for Its Revolutionary Ultra Shear Technology Platform, for Its Innovative NanoGap Valve
Dynamically-Adaptive Compact Valve is Key Component in the Company’s Highly Anticipated and Proprietary UST Platform; UST Expected to Help Deliver Strong Sales Growth and Profitability in 2022
SOUTH EASTON, MA / ACCESSWIRE / November 11, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialized services to the worldwide life sciences, agriculture, cosmetics, food & beverage, and other industries, today announced the award of its second U.S. patent for its revolutionary Ultra Shear Technology™ (UST™) platform. Entitled “Ultrahigh Pressure Compact Valve with Throttling Capability”, this new patent (US 11,156,295) brings the Company’s intellectual property (“IP”) estate to a total of seven UST patents (two in the U.S.) and 30 pressure-based patents worldwide.
The Company’s UST platform was created to revolutionize the processing of immiscible liquids (typically oils and water) – usually processed into macro/micro emulsions – into high quality, highly valuable, long-term stable nanoemulsions. Emulsions are mixtures of two or more liquids that are normally not soluble in each other without the addition of chemicals called emulsifiers (e.g., surfactants). Emulsions are used in thousands of products in everyday use, such as in dairy products, lotions and creams, drugs and vaccines, and nutraceuticals. Scientific data indicate that higher bioavailability and improved absorption in humans, animals and plants, plus greater stability, lower surfactant levels, and other advantages (such as more reliable dosing control) are vastly improved by high quality nanoemulsions versus micro or macroemulsions.
Dr. Edmund Y. Ting, Sr. Vice President of Engineering and an inventor on this patent, said: “The conversion of a coarser emulsion into a high-quality nanoemulsion with ultra-low droplet size is made possible by intense fluid shear forces created from pressure driven fluid velocity. By using pressures up to 60,000 psi to drive fluid flow, we believe that UST achieves a disruptive shear capability greater than any homogenizer on the market today. UST also achieves higher flow rates and lower processing costs than current high-pressure homogenizers by leveraging the use of field proven pumps, patented pressure transfer isolators, and our now patented, self-throttling Nanogap™ valve. The unique design of this compact, self-throttling valve is dynamically-adaptive, delivering clog and erosion resistance, with extraordinary precision and control in producing fine nanoemulsion dispersion size.”
Dr. Alexander V. Lazarev, Chief Science Officer, commented: “We are proud to see our work recognized with yet another strong patent. Amongst the exciting applications of our UST platform are enormous opportunities in the efficient and affordable production of stable nanoemulsions. Nanoemulsions are promising revolutionary advances in food/beverage, nutraceutical, personal care, pharmaceutical, agriculture, as well as many other industries. The UST process features exquisite control of high shear energy, resulting in a very reproducible product with a narrow distribution of droplet sizes as small as 40 to 100 nanometers. Such tiny, nano-sized oil droplets lead to greater stability and higher bioavailability of the active ingredients contained in the oil phase, resulting in more nutritional and better tasting liquid foods and beverages, as well as significantly higher quality drugs and vaccines in dosing and delivery.”
Mr. John B. Hollister , Director of Marketing and Sales, stated, “The daily market interest we are receiving in UST-produced nanoemulsions prior to significant active promotion activities is very exciting. The potential benefits of nanoemulsified products are now recognized by important market leaders globally. The 2021 worldwide market size for a number of industries that could benefit from UST are each in the tens and even hundreds of billions of dollars. Over the past year, we have been working with major players in several of these markets to create unique formulations, the results of which have been embraced by these prospective partners. These companies are exerting tremendous pressure on us to release the commercial-scale, UST systems as quickly as possible. We believe the amount of nanoemulsified product required to meet these customers’ needs will clearly help us achieve our goals of strong sales growth and profitability in 2022.”
For more information on PBI’s innovative UST, BaroFold, and PCT Platforms, and on the Company’s new PBI Agrochem Division, please use the link to follow Mr. Schumacher’s interview on Benzinga’s ALL ACCESS Investor Event on Thursday, November 4, 2021. Schumacher Interview ALL ACCESS 11.4.21
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control biomolecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT- based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g.,oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
Forward Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.
Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.d. Writer is paid $925/mo by company